IP Library Patent Application 12314893
Patent Application
App. No. 12/314,893

Retinoid metabolizing protein

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/314,893
Abstract

Amino acid sequences and corresponding nucleic acid sequence of retinoid metabolizing protein found in human, mouse and zebrafish are described, as well as methods of using same.

Claims (27)

1 . A method of screening drugs for their effect on expression of a gene wherein the gene is inducible by a retinoid, comprising:

(A) exposing a recombinant DNA to a said drug, and

(B) determining the effect on gene expression,

wherein the recombinant DNA comprises:

(i) a nucleotide sequence selected from the group consisting of:

(a) SEQ ID NO:33;

(b) SEQ ID NO:34;

(c) SEQ ID NO:35; and

(d) a fragment of (a), (b) or (c), wherein said DNA fragment possesses promoter activity; and

(ii) at least one structural gene.

2 . The method of claim 1 including exposing the recombinant DNA in the presence of a said retinoid.

3 . The method of claim 1 wherein the at least one structural gene comprises a reporter gene that does not metabolize retinoic acid.

4 . The method of claim 1 wherein the at least one structural gene comprises at least one cytochrome P450.

5 . The method of claim 1 wherein determining the effect on gene expression includes ascertaining the effect on transcription of the gene.

6 . The method of claim 2 wherein the retinoid is a retinoic acid.

7 . The method of claim 6 wherein the retinoic acid is all-trans-retinoic acid.

8 . The method of claim 1 wherein said recombinant DNA includes the sequence TGAACTNNNNNTGAACT, where “N” can be any nucleotide and there can be 0 to 5 N (SEQ ID NO:39).

9 . The method of claim 8 wherein there are 5 N.

10 . The method of claim 8 wherein said recombinant DNA further includes the sequence TCTGASSAAGKTAAC (SEQ ID NO:40) downstream from the sequence TGAACTNNNNNTGAACT (SEQ ID NO:39).

11 . The method of claim 10 wherein said recombinant DNA further includes the sequence AATT between the sequence TGAACTNNNNNTGAACT (SEQ ID NO:39) and the sequence TCTGASSAAGKTAAC (SEQ ID NO:40).

12 . The method of claim 10 wherein there are up to six nucleotides between the sequence TGAACTNNNNNTGAACT (SEQ ID NO:39) and the sequence TCTGASSAAGKTAAC (SEQ ID NO:40).

13 . The method of claim 8 wherein said recombinant DNA further includes the sequence CAATTAAAGA (SEQ ID NO:41) upstream of the sequence TGAACTNNNNNTGAACT (SEQ ID NO:39).

14 . The method of claim 1 wherein said recombinant DNA includes the sequence CAATTAAAGATGAACTTTGGGTGAACTAATT (SEQ ID NO:42).

15 . The method of any of claims 1 to 14 wherein said recombinant DNA includes the sequence TATAA.

16 . The method of claim 8 , 9 or 13 wherein said recombinant DNA includes the sequence TATAA downstream of the sequence TGAACTNNNNNTGAACT (SEQ ID NO:39).

17 . The method of claim 10 or 11 wherein said recombinant DNA includes the sequence TATAA downstream of the sequence TCTGASSAAGKTAAC (SEQ ID NO:40).

18 . The method of claim 8 wherein said recombinant DNA includes the sequence TATAA located downstream of the sequence TGAACTNNNNNTGAACT (SEQ ID NO:39) and spaced up to about 55 nucleotides therefrom.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Aug 31, 2012
From: GENERAL ELECTRIC CAPITAL CORPORATION
To: CYTOCHROMA, INC.; CYTOCHROMA HOLDINGS ULC; PROVENTIV THERAPEUTICS, LLC
Reel/Frame 028881/0338 →
SECURITY AGREEMENT Recorded Sep 28, 2010
From: CYTOCHROMA INC.; PROVENTIV THERAPEUTICS, LLC; CYTOCHROMA HOLDINGS ULC
To: GENERAL ELECTRIC CAPITAL CORPORATION
Reel/Frame 025051/0215 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 22, 2009
From: PETKOVICH, P. MARTIN; WHITE, JAY A.; BECKETT, BARBARA R.; JONES, GLENVILLE
To: QUEEN'S UNIVERSITY AT KINGSTON
Reel/Frame 022578/0618 →